These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26779398)

  • 1. Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM).
    Krymskaya VP
    Expert Opin Orphan Drugs; 2014 Oct; 2(10):1063-1074. PubMed ID: 26779398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).
    Hammes SR; Krymskaya VP
    Horm Cancer; 2013 Apr; 4(2):70-7. PubMed ID: 23184699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
    Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.
    Taveira-DaSilva AM; Moss J
    Expert Opin Orphan Drugs; 2016; 4(4):369-378. PubMed ID: 27833825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    Clin Epidemiol; 2015; 7():249-57. PubMed ID: 25897262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphangioleiomyomatosis: differential diagnosis and optimal management.
    Xu KF; Lo BH
    Ther Clin Risk Manag; 2014; 10():691-700. PubMed ID: 25187723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphangioleiomyomatosis: Current understanding and potential treatments.
    Moir LM
    Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphangioleiomyomatosis.
    Xu KF; Xu W; Liu S; Yu J; Tian X; Yang Y; Wang ST; Zhang W; Feng R; Zhang T
    Semin Respir Crit Care Med; 2020 Apr; 41(2):256-268. PubMed ID: 32279296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
    El-Chemaly S; Goldberg HJ; Glanville AR
    Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular insights into lymphangioleiomyomatosis.
    Steagall WK; Taveira-DaSilva AM; Moss J
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S49-66. PubMed ID: 16457017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.
    Delaney SP; Julian LM; Stanford WL
    Front Cell Dev Biol; 2014; 2():69. PubMed ID: 25505789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
    Johnson J; Somerfield W; Johnson SR
    Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    F1000Prime Rep; 2014; 6():116. PubMed ID: 25580270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberous sclerosis complex for the pulmonologist.
    Rebaine Y; Nasser M; Girerd B; Leroux C; Cottin V
    Eur Respir Rev; 2021 Sep; 30(161):. PubMed ID: 34348978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
    Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
    PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary lymphangioleiomyomatosis in tuberous sclerosis. A case report.
    De Rosa N
    Pathologica; 2009 Oct; 101(5):186-9. PubMed ID: 20218060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
    Krymskaya VP
    Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pulmonary lymphangioleiomyomatosis: report of one case].
    Silva O R; Puelma C F; Retamal P V; Rojas Sm P; Cruzat C C; Reyes G C
    Rev Med Chil; 2009 Nov; 137(11):1474-7. PubMed ID: 20098807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.